Targeting UGCG overcomes resistance to lysosomal autophagy inhibition - PMC
Lysosomal autophagy inhibition (LAI) with hydroxychloroquine or DC661 can enhance cancer therapy, but tumor regrowth is common. To elucidate LAI resistance, proteomics and immunoblotting demonstrated that LAI induced lipid metabolism enzymes in ...
. Author manuscript; available in PMC: 2023 Aug 6. Abstract Lysosomal autophagy inhibition (LAI) with hydroxychloroquine or DC661 can enhance cancer therapy, but tumor regrowth is common. To elucidate LAI resistance, proteomics and immunoblotting demonstrated that LAI induced lipid metabolism enzymes in multiple cancer cell lines. Lipidomics showed that LAI increased cholesterol, sphingolipids, and glycosphingolipids. These changes were associated with striking levels of GM1+ membrane microdomains (GMM) in plasma membranes and lysosomes. Inhibition of cholesterol/sphingolipid metabolism…
saved by
related reading
- UGCG and the glycosphingolipid rheostat: a metabolic checkpoint governing immune activation and tumor immune evasion | Signal Transduction and Targeted Therapynature.com
- Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancernature.com
- A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher diseasepmc.ncbi.nlm.nih.gov
- The roles of glycosphingolipids in the proliferation and neural differentiation of mouse embryonic stem cells - PMCpmc.ncbi.nlm.nih.gov
- Glucosylceramide flippases contribute to cellular glucosylceramide homeostasispmc.ncbi.nlm.nih.gov
- Reconstitution of Glucosylceramide Flip-Flop across Endoplasmic Reticulum: IMPLICATIONS FOR MECHANISM OF GLYCOSPHINGOLIPID BIOSYNTHESISpmc.ncbi.nlm.nih.gov
- Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birthpmc.ncbi.nlm.nih.gov
- Lactosylceramideen.wikipedia.org
- Eliglustat - Wikipediaen.wikipedia.org
- CNIH4: a novel biomarker connected with poor prognosis and cell proliferation in patients with lower-grade gliomapmc.ncbi.nlm.nih.gov
- Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com
- Sphingolipiden.wikipedia.org